Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
about
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Phase Ib/II trial evaluating t ...... metastatic colorectal cancer.
@en
Phase Ib/II trial evaluating t ...... metastatic colorectal cancer.
@nl
type
label
Phase Ib/II trial evaluating t ...... metastatic colorectal cancer.
@en
Phase Ib/II trial evaluating t ...... metastatic colorectal cancer.
@nl
altLabel
Phase Ib/II trial evaluating t ...... h metastatic colorectal cancer
@en
prefLabel
Phase Ib/II trial evaluating t ...... metastatic colorectal cancer.
@en
Phase Ib/II trial evaluating t ...... metastatic colorectal cancer.
@nl
P2093
P2860
P1433
P1476
Phase Ib/II trial evaluating t ...... h metastatic colorectal cancer
@en
P2093
Alice Hervieu
Audrey Hennequin
Aurélie Bertaut
Emilie Rederstorff
Jean-David Fumet
Jean-Florian Guion
Nicolas Isambert
Sylvie Zanetta
P2860
P304
P356
10.1136/ESMOOPEN-2018-000375
P407
P577
2018-06-19T00:00:00Z